156 related articles for article (PubMed ID: 35481133)
21. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach.
Li J; Huang Y; Hutton GJ; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100307. PubMed ID: 37554927
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.
Longbrake EE; Cross AH; Salter A
Mult Scler J Exp Transl Clin; 2016; 2():. PubMed ID: 28280599
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
25. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.
Munsell M; Frean M; Menzin J; Phillips AL
Patient Prefer Adherence; 2017; 11():55-62. PubMed ID: 28115831
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
28. Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness.
Järvinen E; Holmberg M; Sumelahti ML
Neurol Int; 2016 Sep; 8(3):6513. PubMed ID: 27761226
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
31. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT; Saccà F; Lanzillo R; Annovazzi P; Baroncini D; Binello E; Repice A; Perini P; Clerico M; Mataluni G; Bonavita S; La Gioia S; Gutierrez LP; Laroni A; Frau J; Cocco E; Torri Clerici V; Zarbo IR; Sartori A; Signoriello E; Rasia S; Cordioli C; Stromillo ML; Cerqua R; Pontecorvo S; Di Sapio A; Grasso R; Barone S; Lavorgna L; Barrilà C; Landi D; Russo CV; Frigeni B; Ippolito D; Turano G; Carmisciano L; Sormani MP; Signori A
Mult Scler Relat Disord; 2020 Jul; 42():102059. PubMed ID: 32208344
[TBL] [Abstract][Full Text] [Related]
32. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
Tichá V; Počíková Z; Vytlačil J; Štěpánová R
BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
[TBL] [Abstract][Full Text] [Related]
34. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
35. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
36. A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy.
Leist TP; Cole M; Verma S; Keenan A; Le HH
Mult Scler Relat Disord; 2023 Oct; 78():104917. PubMed ID: 37597349
[TBL] [Abstract][Full Text] [Related]
37. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.
Sanford M
Drugs; 2014 Aug; 74(12):1411-33. PubMed ID: 25063048
[TBL] [Abstract][Full Text] [Related]
38. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
[TBL] [Abstract][Full Text] [Related]
39. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Tichá V; Kodým R; Počíková Z; Kadlecová P
Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
[TBL] [Abstract][Full Text] [Related]
40. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]